Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2019 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Positive Omburtamab Clinical Data

NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
October 25, 2019 09:14 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Naxitamab Update

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
August 30, 2019 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Data to be Presented at 2019 CTOS

NEW YORK, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
August 14, 2019 16:05 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Second Quarter 2019 Financial Results and Recent Corporate Developments

NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
August 07, 2019 16:15 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs to Announce Second Quarter 2019 Financial and Operating Results on August 14

NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its second quarter 2019 financial and operating...
July 08, 2019 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Successful Pre-BLA Meeting with FDA for Naxitamab

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
July 01, 2019 09:01 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Recruitment Status for Pivotal Trials

NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
July 01, 2019 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Secures Commercial Radiolabeling Capacity

NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
June 26, 2019 09:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Data to be Presented at 2019 SIOP

NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...
May 15, 2019 17:00 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Data to be Presented at 2019 ASCO Annual Meeting

NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and...